High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 4, 1999, Pages 836-845

  Yoon, Stephanie A ^a   Vazquez, Jose A ^a,b   Steffan, Paul E ^a   Sobel, Jack D ^a   Akins, Robert A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD; CANDIDA ALBICANS; CANDIDA LUSITANIAE; CANDIDIASIS; CELL STRUCTURE; CONTROLLED STUDY; HEAT SHOCK; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

EID: 0032892997     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.4.836     Document Type: Article

References (74)

1. Ahearn, D. G., and M. S. McGlohn. 1984. In vitro susceptibilities of sucrosenegative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole. J. Clin. Microbiol. 19:412-416.
2. Anderson, J. M., and D. R. Soll. 1987. Unique phenotype of opaque cells in the white-opaque transition of Candida albicans. J. Bacteriol. 169:5579-5588.
3. Barchiesi, F., A. L. Colombo, D. A. McGough, and M. G. Rinaldi. 1994. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J. Clin. Microbiol. 32:2494-2500.
4. Bastide, M., S. Jouvert, and J. M. Bastide. 1982. A comparison of the effects of several antifungal imidazole derivatives and polyenes on Candida albicans: an ultrastructural study by scanning electron microscopy. Can. J. Microbiol. 28:1119-1126.
5. Bedell, G. W., and D. R. Soll. 1979. Effects of low concentrations of zinc on the growth and dimorphism of Candida albicans: evidence for zinc-resistant and -sensitive pathways for mycelium formation. Infect. Immun. 26:348-354.
6. Berenguer, J., T. M. Diaz-Guerra, B. Ruiz-Diez, J. C. Bernaldo de Quiros, J. L. Rodriguez-Tudela, and J. V. Martinez-Suarez. 1996. Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient. J. Clin. Microbiol. 34: 1542-1545.
7. Bergen, M. S., E. Voss, and D. R. Soll. 1990. Switching at the cellular level in the white-opaque transition of Candida albicans. J. Gen. Microbiol. 136: 1925-1936.
8. Blumberg, H. M., E. F. Hendershot, and T. J. Lott. 1992. Persistence of the same Candida albicans strain despite fluconazole therapy. Documentation by pulsed-field gel electrophoresis. Diagn. Microbiol. Infect. Dis. 15:545-547.
9. Cassone, A., D. Kerridge, and E. F. Gale. 1979. Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J. Gen. Microbiol. 110:339-349.
10. Cheron, M., B. Cybulska, J. Mazerski, J. Grzybowska, A. Czerwinski, and E. Borowski. 1988. Quantitative structure-activity relationships in amphotericin B derivatives. Biochem. Pharmacol. 37:827-836.
11. Chu, W. S., E. H. Rikkerink, and P. T. Magee. 1992. Genetics of the white-opaque transition in Candida albicans: demonstration of switching recessivity and mapping of switching genes. J. Bacteriol. 174:2951-2957.
12. Clejan, S., and R. Bittman. 1985. Rates of amphotericin B and filipin association with sterols. A study of changes in sterol structure and phospholipid composition of vesicles. J. Biol. Chem. 260:2884-2889.
13. Daneshmend, T. K., and D. W. Warnock. 1983. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8:17-42.
14. De Nollin, S., and M. Borgers. 1975. Scanning electron microscopy of Candida albicans after in vitro treatment with miconazole. Antimicrob. Agents Chemother. 7:704-711.
15. De Nollin, S., and M. Borgers. 1974. The ultrastructure of Candida albicans after in vitro treatment with miconazole. Subouraudia 12:341-351.
16. Dick, J. D., W. G. Merz, and R. Saral. 1980. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob. Agents Chemother. 18:158-163.
17. Gale, E. F., J. Ingram, D. Kerridge, V. Notario, and F. Wayman. 1980. Reduction of amphotericin resistance in stationary phase cultures of Candida albicans by treatment with enzymes. J. Gen. Microbiol. 117:383-391.
18. Gale, E. F., A. M. Johnson, D. Kerridge, and T. Y. Koh. 1975. Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth. J. Gen. Microbiol. 87:20-36.
19. Gale, E. F., A. M. Johnson, D. Kerridge, and F. Waymen. 1980. Phenotypic resistance to miconazole and amphotericin B in Candida albicans. J. Gen. Microbiol. 117:535-538.
20. Ghannoum, M. A., I. Swairjo, and D. R. Soll. Variation in lipid and sterol contents in Candida albicans white and opaque phenotypes. J. Med. Vet. Mycol. 28:103-115.
21. Guinet, R., J. Chanas, A. Goullier, G. Bonnefoy, and P. Ambroise-Thomas. 1983. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J. Clin. Microbiol. 18:443-444.
22. Hadfield, T. L., M. B. Smith, R. E. Winn, M. G. Rinaldi, and C. Guerra. 1987. Mycoses caused by Candida lusitaniae. Rev. Infect. Dis. 9:1006-1012.
23. Jones, S., G. White, and P. R. Hunter. 1994. Increased phenotypic switching in strains of Candida albicans associated with invasive infections. J. Clin. Microbiol. 32:2869-2870.
24. Kelly, S. L., D. C. Lamb, D. E. Kelly, J. Loeffler, and H. Einsele. 1996. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348:1523-1524. (Letter.)
25. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, H. Hebart, U. Schumacher, and H. Einsele. 1997. Resistance to fluconazole and crossresistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol δ-5,6-desaturation. FEBS Lett. 400:80-82.
26. Komshian, S. V., A. K. Uwaydah, J. D. Sobel, and L. R. Crane. 1989. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev. Infect. Dis. 11:379-390.
27. Leberer, E., K. Ziegelbauer, A. Schmidt, D. Harcus, D. Dignard, J. Ash, L. Johnson, and D. Y. Thomas. 1997. Virulence and hyphal formation of Candida albicans require the Ste20p-like protein kinase CaCla4p. Am. J. Clin. Pathol. 108:217-221.
28. Lee, K. L., H. R. Buckley, and C. C. Campbell. 1975. An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida albicans. Sabouraudia. 13:148-153.
29. Lockhart, S. R., J. J. Fritch, A. S. Meier, K. Schroppel, T. Srikantha, R. Galask, and D. R. Soll. 1995. Colonizing populations of Candida albicans are clonal in origin but undergo microevolution through C1 fragment reorganization as demonstrated by DNA fingerprinting and C1 sequencing. J. Clin. Microbiol. 33:1501-1509.
30. Malavasic, M. J., and R. L. Cihlar. 1992. Growth response of several Candida albicans strains to inhibitory concentrations of heavy metals. J. Med. Vet. Mycol. 30:421-432.
31. Marichal, P., J. Gorrens, M. C. Coene, L. Le Jeune, and H. Vanden Bossche. 1995. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 38:111-117.
32. Mas, J., and E. Pina. 1985. Candida resistant to nystatin becomes sensitive upon culture with ergosterol. Arch. Investig. Med. 16:145-155.
33. Mas, J., and E. Pina. Disappearance of nystatin resistance in Candida mediated by ergosterol. J. Gen. Microbiol. 117:249-252.
34. Mathaba, L. T., G. Davies, and J. R. Warmington. 1995. The genotypic relationship of Candida albicans strains isolated from the oral cavity of patients with denture stomatitis. J. Med. Microbiol. 42:372-379.
35. McCullough, M. J., B. C. Ross, B. D. Dwyer, and P. C. Reade. 1994. Genotype and phenotype of oral Candida albicans from patients infected with the human immunodeficiency virus. Microbiology 140:1195-1202.
36. Mercure, S., S. Poirier, G. Lemay, P. Auger, S. Montplaisir, and L. de Repentigny. 1993. Application of hiotyping and DNA typing of Candida albicans to the epidemiology of recurrent vulvovaginal candidiasis. J. Infect. Dis. 168:502-507.
37. Merz, W. G. 1984. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J. Clin. Microbiol. 20:1194-1195.
38. Merz, W. G., U. Khazan, M. A. Jabra-Rizk, L. C. Wu, G. J. Osterhout, and P. F. Lehmann. 1992. Strain delineation and epidemiology of Candida (Clavispora) lusitaniae. J. Clin. Microbiol. 30:449-454.
39. Morrow, B., J. Anderson, J. Wilson, and D. R. Soll. 1989. Bidirectional stimulation of the white-opaque transition of Candida albicans by ultraviolet irradiation. J. Gen. Microbiol. 135:1201-1208.
40. Odds, F. C., and R. Bernaerts. 1994. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J. Clin. Microbiol. 32:1923-1929.
41. Pappagianis, D., M. S. Collins, R. Hector, and J. Remington. 1979. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob. Agents Chemother. 16:123-126.
42. faller, M. A., A. Houston, and S. Coffmann. 1996. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J. Clin. Microbiol. 34:58-61.
43. Pfaller, M. A., S. A. Messer, and R. J. Hollis. 1994. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn. Micobiol. Infect. Dis. 20:127-133.
44. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:826-832.
45. Pujol, C., J. Reynes, F. Renaud, M. Raymond, M. Tibayrenc, F. J. Ayala, K. Janbon, M. Mallie, and J. M. Bastide. 1993. The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients. Proc. Natl. Acad. Sci. USA 90:9456-9459.
46. Radford, D. R., S. J. Challcombe, and J. D. Walter. 1997. Scanning electron microscopy of the development of structured aerial mycelia and satellite colonies of phenotypically switched Candida albicans. J. Med. Microbiol. 46: 326-332.
47. Radford, D. R., S. J. Challacombe, and J. D. Walter. 1994. A scanning electronmicroscopy investigation of the structure of colonies of different morphologies produced by phenotypic switching of Candida albicans. J. Med. Microbiol. 40:416-423.
48. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a brothbased system. Antimicrob. Agents Chemother. 39:906-909.
49. Rikkerink, E. H., B. B. Magee, and P. T. Magee. 1988. Opaque-white phenotype transition: a programmed morphological transition in Candida albicans. J. Bacteriol. 170:895-899.
50. Sanchez, P. J., and B. H. Cooper. 1987. Candida lusitaniae: sepsis and meningitis in a neonate. Pediatr. Infec. Dis. J. 6:758-759.
51. Sanchez, V., J. A. Vazqnez, D. Barth-Jones, L. Dembry, J. D. Sobel, and M. J. Zervos. 1992. Epidemiology of nosocomial acquisition of Candida lusitaniae. J. Clin. Microbiol. 30:3005-3008.
52. Scheven, M., and F. Schwegler. 1995. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob. Agents Chemother. 39:1779-1783.
53. Schonian, G., O. Meusel, H. J. Tietz, W. Meyer, Y. Graser, I. Tausch, W. Presber, and T. G. Mitchell. 1993. Identification of clinical strains of Candida albicans by DNA fingerprinting with the polymerase chain reaction. Mycoses 36:171-179.
54. Slutsky, B., J. Buffo, and D. R. Soll. 1985. High-frequency switching of colony morphology in Candida albicans. Science 230:666-669.
55. Slutsky, B., M. Staebell, J. Anderson, L. Risen, M. Pfaller, and D. R. Soll. 1987. "While-opaque transition": a second high-frequency switching system in Candida albicans. J. Bacteriol. 169:189-197.
56. Soll, D. R. 1996. The emerging molecular biology of switching in Candida albicans. ASM News 62:415-420.
57. Soll, D. R. 1997. Gene regulation during high-frequency switching in Candida albicans. Microbiology 143:279-288.
58. Soll, D. R. 1992. High-frequency switching in Candida albicans. Clin. Microbiol. Rev. 5:183-203.
59. Soll, D. R., R. Galask, S. Isley, T. V. Rao, D. Stone, J. Hicks, J. Schmid, K. Mac, and C. Hanna. 1989. Switching of Candida albicans during successive episodes of recurrent vaginitis. J. Clin. Microbiol. 27:681-690.
60. Soll, D. R., B. Morrow, and T. Srikantha. 1993. High-frequency phenotypic switching in Candida albicans. Trends Genet. 9:61-65.
61. Soll, D. R., B. Morrow, T. Srikantha, K. Vargas, and P. Wertz. 1994. Developmental and molecular biology of switching in Candida albicans. Oral Surg. Oral Med. Oral Pathol. 78:194-201.
62. Soll, D. R., M. Staebell, C. Langtimm, M. Pfaller, J. Hicks, and T. V. Rao. 1988. Multiple Candida strains in the course of a single systemic infection. J. Clin. Microbiol. 26:1448-1459.
63. Spinillo, A., E. Capuzzo, T. O. Egbe, F. Baltaro, S. Nicola, and G. Piazzi. 1995. Torulopsis glabrata vaginitis. Obstet. Gynecol. 85:993-998.
64. Steffan, P., J. A. Vazquez, D. Boikov, C. Xu, J. D. Sobel, and R. A. Akins. 1997. Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates. J. Clin. Microbiol. 35:2031-2039.
65. a. Steffan, P., J. A. Vazquez, and R. A. Akins. Unpublished data.
66. Sud, I. J., and D. S. Feingold. 1983. Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrob. Agents Chemother. 23:185-187.
67. Thanos, M., G. Schonian, W. Meyer, C. Schweynoch, Y. Graser, T. G. Mitchell, W. Presber, and H. J. Tietz. 1996. Rapid identification of Candida species by DNA fingerprinting with PCR. J. Clin. Microbiol. 34:615-621.
68. Vazquez, J. A., M. T. Arganoza, J. K. Vaishampayan, and R. A. Akins. 1996. In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrob. Agents Chemother. 40:2511-2516.
69. Vazquez, J. A., A. Beckley, S. Donabedian, J. D. Sobel, and M. J. Zervos. 1993. Comparison of restriction enzyme analysis versus pulsed-field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicans. J. Clin. Microbiol. 31:2021-2030.
70. Vazquez, J. A., T. Lundstrom, L. Dembry, P. Chandrasekar, D. Boikov, M. B. Parri, and M. J. Zervos. 1995. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Bone Marrow Transplant. 16:849-853.
71. Vazquez, J. A., J. D. Sobel, R. Demitriou, J. Vaishampayan, M. Lynch, and M. J. Zervos. 1994. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J. Infect. Dis. -170:1566-1569.
72. Velegraki, A. 1995. In vitro susceptibility to itraconazole and fluconazole of switch phenotypes of Candida albicans serotypes A and B, isolated from immunocompromised hosts. J. Med. Vet. Mycol. 33:83-85.
73. Wendt, B., L. Haglund, A. Razavi, and R. Rath. 1998. Candida lusitaniae: an uncommon cause of prosthetic valve endocarditis. Clin. Infect. Dis. 26:769-770.
74. Williams, J. G., A. R. Kubelik, K. J. Livak, J.A. Rafalski, and S. V. Tingey. 1990. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. Nucleic Acids Res. 18:6531-6535.